MedTrace Logo

Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness

NCT01018225 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2016-04-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of darifenacin in the treatment of moderate to severe nocturia in patients with overactive bladder and who do not have non-urologic causes of nocturia.

Conditions

  • Nocturia

Interventions

DRUG

darifenacin

7.5 or 15 mg darifenacin, once a day for 6 weeks

DRUG

Placebo

Placebo pill, once a day, for six weeks

Sponsors & Collaborators

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Completion
2010-07-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01018225 on ClinicalTrials.gov